CBS 2019
CBSMD教育中心
中 文

DAPT Duration

Abstract

Recommended Article

Conceptual Framework for Addressing Residual Atherosclerotic Cardiovascular Disease Risk in the Era of Precision Medicine Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome: The TICO Randomized Clinical Trial Impact of bleeding during dual antiplatelet therapy in patients with coronary artery disease Patient-tailored antithrombotic therapy following percutaneous coronary intervention Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial Comparison of 1-month Versus 12-month Dual Antiplatelet Therapy after Implantation of Drug-eluting Stents Guided by either Intravascular Ultrasound or Angiography in Patients with Acute Coronary Syndrome: Rationale and Design of Prospective, Multicenter, Randomized, Controlled IVUS-ACS & ULTIMATE-DAPT trial Safety and efficacy of the bioabsorbable polymer everolimus-eluting stent versus durable polymer drug-eluting stents in high-risk patients undergoing PCI: TWILIGHT-SYNERGY

Clinical TrialMarch 17, 2019

JOURNAL:N Engl J Med. Article Link

Antibody-Based Ticagrelor Reversal Agent in Healthy Volunteers

DL Bhatt, CV Pollack, JS Lee et al. Keywords: Ticagrelor reversal; oral P2Y12 inhibitor; major bleeding

FULL TEXT PDF